Adverse events after ICI treatment linked to improved outcomes in patients with melanoma
Source: Healio, September 2023
Key takeaways:
- Cutaneous immune-related adverse events (cirAEs) were associated with improved overall survival (HR = 0.61).
- CirAEs were also associated with progression-free survival (HR = 0.52).
Patients that experience cutaneous immune-related adverse events after immune checkpoint inhibitor treatment are more likely to survive their melanoma diagnosis, according to a study.
“Over the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape for patients with advanced malignant tumors,” Yaxin Du, BM, of the department of dermatology, Zhongda Hospital, School of Medicine at Southeast University in Nanjing, China, and colleagues wrote.